title: FGF-23 in patients with end-stage renal disease on hemodialysis.
abstract: BACKGROUND
  Fibroblast growth factor (FGF)-23 is a recently identified circulating factor which causes renal phosphate wasting disorders. Although the mechanism of regulation of FGF-23 secretion is unknown, plasma FGF-23 level may be regulated or affected by serum phosphate levels because of its hypophosphatemic effect.
  
  
  METHODS
  We tested the hypothesis that plasma FGF-23 levels may be increased in hyperphosphatemia in patients with end-stage renal disease (ESRD) on maintenance hemodialysis. We measured plasma FGF-23 levels in 158 male uremic patients on maintenance hemodialysis. Plasma samples were obtained before starting dialysis sessions to determine FGF-23 levels by enzyme-linked immunosorbent assay (ELISA).
  
  
  RESULTS
  Plasma FGF-23 level exhibited significant and positive correlations with inorganic phosphate, intact parathyroid hormone (PTH), corrected calcium, and duration of hemodialysis on simple regression analyses. All these associations remained significant in multiple regression analyses.
  
  
  CONCLUSIONS
  Serum phosphate, calcium, and intact PTH could be regulators of FGF-23 levels in uremic patients on maintenance hemodialysis. Our results may provide new insights into the pathophysiologic effects of FGF-23 on calcium-phosphate homeostasis.
authors.affiliation: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan. imanishi@med.osaka-cu.ac.jp
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Imanishi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Inaba
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Nakatsuka
authors.forename: Kyoko
authors.initials: K
authors.lastname: Nagasue
authors.forename: Senji
authors.initials: S
authors.lastname: Okuno
authors.forename: Asami
authors.initials: A
authors.lastname: Yoshihara
authors.forename: Masakazu
authors.initials: M
authors.lastname: Miura
authors.forename: Akimitsu
authors.initials: A
authors.lastname: Miyauchi
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Takami
authors.initials: T
authors.lastname: Miki
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Shoji
authors.forename: Eiji
authors.initials: E
authors.lastname: Ishimura
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Nishizawa
mesh_terms: D016022:Case-Control Studies; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis
chemical_list: C000717427:FGF23 protein, human; D010281:Parathyroid Hormone; D010710:Phosphates; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23